GlassScriptPhysician profile
Anne K Mcbride
NPI 1013981364
$5,767.65
in general payments reported to CMS, 2019-2025
28 companies · $1,861 in 2025
The $1,861 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $559 · 2020: $412 · 2021: $333 · 2022: $637 · 2023: $623 · 2024: $1,342 · 2025: $1,861.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,661 · Education: $165.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,661.27 |
| Education | $165.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,258.38 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $450.97 | 2019-2025 | |
| Janssen Biotech, INC. | $447.30 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| E.R. Squibb & Sons, L.L.C. | $405.71 | 2023-2025 | Sotyktu |
| Genzyme Corporation | $399.66 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $344.31 | 2019-2025 | Dupixent, Libtayo |
| Sun Pharmaceutical Industries INC. | $323.91 | 2019-2025 | Odomzo, Blu-U |
| Ucb, INC. | $322.52 | 2021-2025 | Bimzelx |
| Pfizer INC. | $310.00 | 2019-2025 | |
| Lilly USA, LLC | $255.54 | 2020-2025 | Ebglyss, Taltz, Olumiant |
| Boehringer Ingelheim Pharmaceuticals, INC. | $169.23 | 2022-2025 | Spevigo |
| Incyte Corporation | $154.90 | 2021-2023 | Opzelura |
| Arcutis Biotherapeutics, INC. | $150.50 | 2025 | Zoryve |
| Genentech USA, INC. | $132.85 | 2019-2020 | |
| Galderma Laboratories, L.P. | $117.14 | 2020-2025 | Nemluvio |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $94.61 | 2021-2025 | Otezla, Otezla |
| Dusa Pharmaceuticals, INC. | $57.55 | 2019 | |
| Kyowa Kirin, INC. | $55.71 | 2023-2025 | Poteligeo |
| Almirall LLC | $55.43 | 2022-2024 | Seysara |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $41.52 | 2019 | |
| Leo Pharma INC. | $39.05 | 2020-2025 | Adbry |
| Organon LLC | $36.23 | 2025 | |
| Vyne Pharmaceuticals INC. | $31.55 | 2020 | |
| Dermavant Sciences, INC. | $29.96 | 2024 | Vtama |
| Strata Skin Sciences, INC. | $26.57 | 2024 | Xtrac |
| Organogenesis INC. | $20.43 | 2023 | Puraply |
| Botanix Sb INC | $20.00 | 2025 | Sofdra |
| Mayne Pharma Commercial LLC | $16.12 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anne Mcbride listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.